Work

Evaluation of Premarket-Identified Serious Risks for Drugs and Biologics Using FDA Surveillance Systems

Year: 2026
Type: article
Study design: Observational Study
Abstract: This cross-sectional study examines the use and sufficiency of US Food and Drug Administration (FDA) postmarket surveillance systems for further assessing serious risks found at product approval between 2016 and 2025.
Language: English
Subfield: Toxicology
Open Access status: green
OpenAlex ID: W7234452154
FWCI:
Cites: 9
Cited by:
Related to: 10